Ovarian Cancer

After eight years with no new treatments for ovarian cancer, PARP inhibitors and anti-angiogenics are benefiting patients.

Shana Wingo, M.D., discussed advancements being made in the field of surgery for patients with gynecologic cancers.

A recent study examined common co-morbidities, such as diabetes, heart disease and hypertension, and their effects on ovarian cancer survival.

Shana Wingo, M.D., discusses surgery's changing role in the treatment of ovarian cancer.

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

The FDA has approved Zejula (niraparib) for treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the maintence setting.

Results from a randomized trial suggest maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy do not improve overall survival rates among women with ovarian cancer who had achieved remission.

Hormonal maintenance therapy may be able to improve PFS rates for some patients with ovarian cancer, according to a recent study.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.